And so I think it's quite rational knowing what we know about the immunobiology to couple it with checkpoints with uh a novel cytokine like agent like Nemvolleukin. Uh, but I also think, uh, that there are some opportunities to think more broadly, um, and so let's just tick those off one by 11 is to go after m known immunologically responsive tumors, uh, either to checkpoints or IL2 itself, and I think those are low hanging fruits just to get proof of uh con uh. Concept, uh, but I also think moving into other tumors for which we know T cells play a critical role in the biology since they're associated with improved prognosis such as um. MS stable colorectal cancer, such as uh ovarian cancer, etc. is quite rational because here's a situation in which uh endogenous T cells, if given a novel cytokine like nevolleukin, uh, could potentially be, uh, enabled to mediate important anti-tumor effects. Uh, I also think that the, uh, notion of uh bringing this therapy. Uh, into earlier line therapies, uh, exists. I think if you look critically at our dozen years of checkpoint, uh, development, what we've seen is, uh, it's initial testing in lateline, uh, uh, therapies in patients with lung cancer, melanoma, kidney cancer, etc. But an increasing appreciation that it could be applied in earlier settings, um, Not only uh as first or second line therapy, but I think most excitingly to me as a cancer clinician, uh, as a neoadjuvant therapy where you administer it prior to surgical excision uh of a uh tumor, uh, and probably of all the things that has happened in the last couple of years, the emergence of Neoadjuvant therapies showing a 20% as much as a 20% improvement in long-term survival when directly compared to adjuvant therapy with the same checkpoint and uh blockers, uh, suggests to me that it has different biologic activity when given in that setting. Uh, and so looking way ahead, recognizing this is highly speculative, it's gonna wait for the additional data coming initially from their phase 3 studies, but it's conceivable to me that not only could you see an envelo and moving uh into earlier line therapies for conventionally, um, Immunotherapeutically responsive tumors, but potentially also move uh in combination with chemotherapy, with radiation therapy, and potentially as new adjuvant therapies as the checkpoint blockade uh agents uh have done. So I, I see an opportunity at least, if you're an optimist as I am as a cancer clinician, that it could have quite a interesting opportunity for development.
Presenter
